Cite
Stimulated Expression of CXCL12 in Adrenocortical Carcinoma by the PPARgamma Ligand Rosiglitazone Impairs Cancer Progression
MLA
Massimo Mannelli, et al. Stimulated Expression of CXCL12 in Adrenocortical Carcinoma by the PPARgamma Ligand Rosiglitazone Impairs Cancer Progression. Oct. 2021. EBSCOhost, widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsair&AN=edsair.doi.dedup.....cda57db2250fd8c3f3af30772778a822&authtype=sso&custid=ns315887.
APA
Massimo Mannelli, Maria Lucia Angelotti, Michela Francalanci, Letizia Canu, Constanze Hantel, Giulia Cantini, Stefania Gelmini, Gabriella Nesi, Tonino Ercolino, Mario Maggi, Michaela Luconi, Laura Fei, Giuseppina De Filpo, Monica Mangoni, Elena Lazzeri, & Mariangela Sottili. (2021). Stimulated Expression of CXCL12 in Adrenocortical Carcinoma by the PPARgamma Ligand Rosiglitazone Impairs Cancer Progression.
Chicago
Massimo Mannelli, Maria Lucia Angelotti, Michela Francalanci, Letizia Canu, Constanze Hantel, Giulia Cantini, Stefania Gelmini, et al. 2021. “Stimulated Expression of CXCL12 in Adrenocortical Carcinoma by the PPARgamma Ligand Rosiglitazone Impairs Cancer Progression,” October. http://widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsair&AN=edsair.doi.dedup.....cda57db2250fd8c3f3af30772778a822&authtype=sso&custid=ns315887.